CytoCore's Director of Research Appears on "Your Cancer Today" Broadcast.Dr. George Gorodeski Discusses Advances in Early Screening for Reproductive Cancers CHICAGO -- Dr. George Gorodeski, director of research at CytoCore, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CYCR), will appear this week on the nationally distributed cable program "Your Cancer Today" to discuss the late-stage bio-scientific research company's breakthrough suite of cervical, endometrial endometrial /en·do·me·tri·al/ (en?do-me´tre-il) pertaining to the endometrium. endometrial, n relating to the end-ometrium or cavity of the uterus. and uterine cancer uterine cancer Malignant tumour of the uterus. Cancers affecting the lining of the uterus (endometrium) are the most common cancers of the female reproductive tract. screening, diagnostic and treatment products. Dr. Gorodeski, a faculty member at University Hospital Case Medical Center of Cleveland, highlights in an in-depth interview CytoCore's current clinical trials on a cutting-edge endometrial cancer Endometrial Cancer Definition Endometrial cancer develops when the cells that make up the inner lining of the uterus (the endometrium) become abnormal and grow uncontrollably. scan that could potentially save the lives of tens of thousands of women diagnosed each year with the disease. He also discusses his work with the P2X7 biomarker, a highly sensitive Adj. 1. highly sensitive - readily affected by various agents; "a highly sensitive explosive is easily exploded by a shock"; "a sensitive colloid is readily coagulated" and accurate indicator of cancerous and pre-cancerous epithelial cells Epithelial cells Cells that form a thin surface coating on the outside of a body structure. Mentioned in: Corneal Transplantation , as well as CytoCore's e2Collector, an innovative and non-invasive method of collecting cervical cell samples. The "Your Cancer Today" edition featuring Dr. Gorodeski will be broadcast on local cable television outlets regionally across the nation, including greater Los Angeles on Thursday evening, November 30th and in the New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of area on Friday evening, December 1st. Further information and local programming details about Dr. Gorodeski's appearance on "Your Cancer Today" are available at www.yourcancertoday.com. Further information about CytoCore, Inc., is available at www.CytoCoreInc.com. About CytoCore Inc. CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The InPath[TM] System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com Dr. Gorodeski has a significant financial interest in this research consisting of equity and salary as consultant and Director of the Scientific Advisory Board of CytoCore. Dr. Gorodeski's invention licensed to CytoCore may generate royalty income for Dr. Gorodeski, for University Hospitals of Cleveland University Hospitals is a major not-for-profit medical center in Cleveland, Ohio, United States. With 150 locations throughout northeast Ohio, it encompasses a network of hospitals, outpatient centers and primary care physicians. , and for CASE University. Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath[TM] System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion